29 research outputs found
ACUTE POST COMPLICATIONS IN STROKE PATIENTS VISITING A TERTIARY TEACHING HOSPITAL
Objective: The study was focused on assessing the incidence of stroke and their association with types of the risk factor, with an emphasis on acute post complications and their symptomatic management for early detection.Methods: A prospective observational study was carried out on stroke patients visiting a medicine department of a tertiary hospital, Andhra Pradesh, India from August 2017 to November 2017. Patient's demographics and lab data was collected for analysis.Results: A total of 110 patients participated in the study. Among them high incidence is males (69%), 61-80yrs (48%), with 2 risk factors (35%) among which age (67%) and hypertension (66%) were related to the high degree of prevalence. 47% of the study population were identified with one complication, among which seizures account for 38% of patients. All the complications associated with the condition were treated with drug classes, in which anti-epileptic drugs (AEDs) were the mainstay in the management of epilepsy.Conclusion: Brain edema and seizure attack were the most accountable complications identified in the study population. The early detection of these problems can improve the stroke outcomes and can reduce the mortality or disability rate
Marine Biodiversity Museum (A Designated National Repository) Catalogue
The Central Marine Fisheries Research Institute, Cochin was
recognized as a 'Designated National Repository' by the Government of
India, in December 2007 in consultation with the National Biodiversity
Authority under the Biological Diversity Act, 2002. A Designated National
Repository (DNR) is an Institution authorised to keep in safe custody
specimens of different categories of biological material.
The Museum offers a glimpse of the bioresources of the Indian seas.
Currently the museum houses six holotype specimens, 878 finfish species,
136 crustaceans, 217 molluscs, 44 echinoderms, 162 corals, 12 sponges,
20 ascidians, 82 seaweeds and 8 seagrasses besides a dolphin and three
Antarctic birds. The Museum is open to scientists, teachers, students
and the general public. The fact that students form more than 85% of the
visitors highlights the role played by the Museum in education.
A catalogue of the specimens available in the Museum has been
prepared as it is expected to be of immense use to those engaged in
marine biodiversity studies. I sincerely thank Dr. G. Syda Rao, Director,
CMFRI whose guidance and encouragement made this a reality
Screening groundnut genotypes using TIR (Temperature Induction Response) technique for thermotolerance
Heat is one of the major abiotic stresses that adversely affect
crop production worldwide at different stages of development.
Groundnut is a major crop cultivated in tropical and sub-tropical
regions where high temperature stress is a serious constraint
for its production. In the present study, temperature induction
response (TIR) was conducted for screening the tolerant genotypes,
where the seedlings were exposed to sublethal temperature
from 34ºC-54ºC for 4 hours 30 minutes followed by lethal
temperature at 58ºC for 3 hours. From the 100 diverse genotypes
screened, 24 showed tolerance to high temperature with mean
percent seedling survival of 92%, 30 showed moderate tolerance
and 46 were identified as temperature susceptible compared
with checks (100% survival). Results suggested that TIR is used
to identify stable thermotolerant genotypes and could be explored
as donor source useful in breeding programmes. Further
work will be focused on the physiological and molecular basis of
thermotolerance in selected tolerant and susceptible genotypes
for the identification of heat stress tolerant genes which could
be useful for engineering plants with improved heat tolerance
New distributional record of the insular shelf beauty Symphysanodon typus Bleeker, 1878 (Family: Symphysanodontidae) from Indian waters
The family Symphysanodontidae comprises of
small to medium sized bony fishes commonly known
as banquelovelies, slopefishes and insular shelf
beauties. They are caught in trawls operating in
depths from 50 to 500 m, mainly on the continental
shelf and slopes
Sputum conversion at the end of intensive phase of Category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: An analysis of risk factors
Background & objectives: New smear-positive pulmonary tuberculosis (PTB) patients in the Revised
National Tuberculosis Control Programme (RNTCP) are treated with a 6-month short-course
chemotherapy (SCC) regimen irrespective of co-morbid conditions. We undertook this retrospective
analysis to compare sputum conversion rates (smear, culture) at the end of intensive phase (IP) of
Category-1 regimen among patients admitted to concurrent controlled clinical trials: pulmonary
tuberculosis alone (PTB) or with type 2 diabetes mellitus (DM-TB) or HIV infection (HIV-TB), and
to identify the risk factors influencing sputum conversion.
Methods: In this retrospective analysis sputum conversion rates at the end of intensive phase (IP) in
three concurrent studies undertaken among PTB, DM-TB and HIV-TB patients, during 1998 –
2002 at the Tuberculosis Research Centre (TRC), Chennai, were compared. Sputum smears were
examined by fluorescent microscopy. HIV infected patients did not receive anti-retroviral treatment
(ART). Patients with DM were treated with oral hypoglycaemic drugs or insulin (sc).
Results: The study population included 98, 92 and 88 patients in the PTB, DM-TB and HIV-TB
studies. At the end of IP the smear conversion (58, 61, and 62%) and culture conversion (86, 88 and
92%) rates were similar in the three groups respectively. The variables associated with lack of
sputum smear or culture conversion were age >45 yr, higher pre-treatment smear and culture grading,
and extent of the radiographic involvement.
Interpretation & conclusions: Our findings confirm that the current policy of the control programme
to treat all pulmonary TB patients with or with out co-morbid conditions with Category-I regimen
appears to be appropriate
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
Background: Estimates of demographic metrics are crucial to assess levels and trends of population health outcomes. The profound impact of the COVID-19 pandemic on populations worldwide has underscored the need for timely estimates to understand this unprecedented event within the context of long-term population health trends. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides new demographic estimates for 204 countries and territories and 811 additional subnational locations from 1950 to 2021, with a particular emphasis on changes in mortality and life expectancy that occurred during the 2020–21 COVID-19 pandemic period. Methods: 22 223 data sources from vital registration, sample registration, surveys, censuses, and other sources were used to estimate mortality, with a subset of these sources used exclusively to estimate excess mortality due to the COVID-19 pandemic. 2026 data sources were used for population estimation. Additional sources were used to estimate migration; the effects of the HIV epidemic; and demographic discontinuities due to conflicts, famines, natural disasters, and pandemics, which are used as inputs for estimating mortality and population. Spatiotemporal Gaussian process regression (ST-GPR) was used to generate under-5 mortality rates, which synthesised 30 763 location-years of vital registration and sample registration data, 1365 surveys and censuses, and 80 other sources. ST-GPR was also used to estimate adult mortality (between ages 15 and 59 years) based on information from 31 642 location-years of vital registration and sample registration data, 355 surveys and censuses, and 24 other sources. Estimates of child and adult mortality rates were then used to generate life tables with a relational model life table system. For countries with large HIV epidemics, life tables were adjusted using independent estimates of HIV-specific mortality generated via an epidemiological analysis of HIV prevalence surveys, antenatal clinic serosurveillance, and other data sources. Excess mortality due to the COVID-19 pandemic in 2020 and 2021 was determined by subtracting observed all-cause mortality (adjusted for late registration and mortality anomalies) from the mortality expected in the absence of the pandemic. Expected mortality was calculated based on historical trends using an ensemble of models. In location-years where all-cause mortality data were unavailable, we estimated excess mortality rates using a regression model with covariates pertaining to the pandemic. Population size was computed using a Bayesian hierarchical cohort component model. Life expectancy was calculated using age-specific mortality rates and standard demographic methods. Uncertainty intervals (UIs) were calculated for every metric using the 25th and 975th ordered values from a 1000-draw posterior distribution. Findings: Global all-cause mortality followed two distinct patterns over the study period: age-standardised mortality rates declined between 1950 and 2019 (a 62·8% [95% UI 60·5–65·1] decline), and increased during the COVID-19 pandemic period (2020–21; 5·1% [0·9–9·6] increase). In contrast with the overall reverse in mortality trends during the pandemic period, child mortality continued to decline, with 4·66 million (3·98–5·50) global deaths in children younger than 5 years in 2021 compared with 5·21 million (4·50–6·01) in 2019. An estimated 131 million (126–137) people died globally from all causes in 2020 and 2021 combined, of which 15·9 million (14·7–17·2) were due to the COVID-19 pandemic (measured by excess mortality, which includes deaths directly due to SARS-CoV-2 infection and those indirectly due to other social, economic, or behavioural changes associated with the pandemic). Excess mortality rates exceeded 150 deaths per 100 000 population during at least one year of the pandemic in 80 countries and territories, whereas 20 nations had a negative excess mortality rate in 2020 or 2021, indicating that all-cause mortality in these countries was lower during the pandemic than expected based on historical trends. Between 1950 and 2021, global life expectancy at birth increased by 22·7 years (20·8–24·8), from 49·0 years (46·7–51·3) to 71·7 years (70·9–72·5). Global life expectancy at birth declined by 1·6 years (1·0–2·2) between 2019 and 2021, reversing historical trends. An increase in life expectancy was only observed in 32 (15·7%) of 204 countries and territories between 2019 and 2021. The global population reached 7·89 billion (7·67–8·13) people in 2021, by which time 56 of 204 countries and territories had peaked and subsequently populations have declined. The largest proportion of population growth between 2020 and 2021 was in sub-Saharan Africa (39·5% [28·4–52·7]) and south Asia (26·3% [9·0–44·7]). From 2000 to 2021, the ratio of the population aged 65 years and older to the population aged younger than 15 years increased in 188 (92·2%) of 204 nations. Interpretation: Global adult mortality rates markedly increased during the COVID-19 pandemic in 2020 and 2021, reversing past decreasing trends, while child mortality rates continued to decline, albeit more slowly than in earlier years. Although COVID-19 had a substantial impact on many demographic indicators during the first 2 years of the pandemic, overall global health progress over the 72 years evaluated has been profound, with considerable improvements in mortality and life expectancy. Additionally, we observed a deceleration of global population growth since 2017, despite steady or increasing growth in lower-income countries, combined with a continued global shift of population age structures towards older ages. These demographic changes will likely present future challenges to health systems, economies, and societies. The comprehensive demographic estimates reported here will enable researchers, policy makers, health practitioners, and other key stakeholders to better understand and address the profound changes that have occurred in the global health landscape following the first 2 years of the COVID-19 pandemic, and longer-term trends beyond the pandemic
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
Background: Understanding the health consequences associated with exposure to risk factors is necessary to inform public health policy and practice. To systematically quantify the contributions of risk factor exposures to specific health outcomes, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 aims to provide comprehensive estimates of exposure levels, relative health risks, and attributable burden of disease for 88 risk factors in 204 countries and territories and 811 subnational locations, from 1990 to 2021. Methods: The GBD 2021 risk factor analysis used data from 54 561 total distinct sources to produce epidemiological estimates for 88 risk factors and their associated health outcomes for a total of 631 risk–outcome pairs. Pairs were included on the basis of data-driven determination of a risk–outcome association. Age-sex-location-year-specific estimates were generated at global, regional, and national levels. Our approach followed the comparative risk assessment framework predicated on a causal web of hierarchically organised, potentially combinative, modifiable risks. Relative risks (RRs) of a given outcome occurring as a function of risk factor exposure were estimated separately for each risk–outcome pair, and summary exposure values (SEVs), representing risk-weighted exposure prevalence, and theoretical minimum risk exposure levels (TMRELs) were estimated for each risk factor. These estimates were used to calculate the population attributable fraction (PAF; ie, the proportional change in health risk that would occur if exposure to a risk factor were reduced to the TMREL). The product of PAFs and disease burden associated with a given outcome, measured in disability-adjusted life-years (DALYs), yielded measures of attributable burden (ie, the proportion of total disease burden attributable to a particular risk factor or combination of risk factors). Adjustments for mediation were applied to account for relationships involving risk factors that act indirectly on outcomes via intermediate risks. Attributable burden estimates were stratified by Socio-demographic Index (SDI) quintile and presented as counts, age-standardised rates, and rankings. To complement estimates of RR and attributable burden, newly developed burden of proof risk function (BPRF) methods were applied to yield supplementary, conservative interpretations of risk–outcome associations based on the consistency of underlying evidence, accounting for unexplained heterogeneity between input data from different studies. Estimates reported represent the mean value across 500 draws from the estimate's distribution, with 95% uncertainty intervals (UIs) calculated as the 2·5th and 97·5th percentile values across the draws. Findings: Among the specific risk factors analysed for this study, particulate matter air pollution was the leading contributor to the global disease burden in 2021, contributing 8·0% (95% UI 6·7–9·4) of total DALYs, followed by high systolic blood pressure (SBP; 7·8% [6·4–9·2]), smoking (5·7% [4·7–6·8]), low birthweight and short gestation (5·6% [4·8–6·3]), and high fasting plasma glucose (FPG; 5·4% [4·8–6·0]). For younger demographics (ie, those aged 0–4 years and 5–14 years), risks such as low birthweight and short gestation and unsafe water, sanitation, and handwashing (WaSH) were among the leading risk factors, while for older age groups, metabolic risks such as high SBP, high body-mass index (BMI), high FPG, and high LDL cholesterol had a greater impact. From 2000 to 2021, there was an observable shift in global health challenges, marked by a decline in the number of all-age DALYs broadly attributable to behavioural risks (decrease of 20·7% [13·9–27·7]) and environmental and occupational risks (decrease of 22·0% [15·5–28·8]), coupled with a 49·4% (42·3–56·9) increase in DALYs attributable to metabolic risks, all reflecting ageing populations and changing lifestyles on a global scale. Age-standardised global DALY rates attributable to high BMI and high FPG rose considerably (15·7% [9·9–21·7] for high BMI and 7·9% [3·3–12·9] for high FPG) over this period, with exposure to these risks increasing annually at rates of 1·8% (1·6–1·9) for high BMI and 1·3% (1·1–1·5) for high FPG. By contrast, the global risk-attributable burden and exposure to many other risk factors declined, notably for risks such as child growth failure and unsafe water source, with age-standardised attributable DALYs decreasing by 71·5% (64·4–78·8) for child growth failure and 66·3% (60·2–72·0) for unsafe water source. We separated risk factors into three groups according to trajectory over time: those with a decreasing attributable burden, due largely to declining risk exposure (eg, diet high in trans-fat and household air pollution) but also to proportionally smaller child and youth populations (eg, child and maternal malnutrition); those for which the burden increased moderately in spite of declining risk exposure, due largely to population ageing (eg, smoking); and those for which the burden increased considerably due to both increasing risk exposure and population ageing (eg, ambient particulate matter air pollution, high BMI, high FPG, and high SBP). Interpretation: Substantial progress has been made in reducing the global disease burden attributable to a range of risk factors, particularly those related to maternal and child health, WaSH, and household air pollution. Maintaining efforts to minimise the impact of these risk factors, especially in low SDI locations, is necessary to sustain progress. Successes in moderating the smoking-related burden by reducing risk exposure highlight the need to advance policies that reduce exposure to other leading risk factors such as ambient particulate matter air pollution and high SBP. Troubling increases in high FPG, high BMI, and other risk factors related to obesity and metabolic syndrome indicate an urgent need to identify and implement interventions
Effective management of mandibular Grade III furcation: A dicey issue
The changing perspectives in dentistry aim at retaining functionally active teeth with an adequate amount of healthy supporting tissues. One such treatment opportunity available is for the management of teeth with furcation involvement, which in earlier times was attributed with a guarded prognosis. Treatment of teeth with these lesions is an uphill task for the clinician and maintenance after treatment also poses a problem to the patient due to anatomical variations, which favor the growth of micro-organisms. Teeth with furcation involvement can be maintained in a state of function for a longer period of time if appropriately treated, and if the patient is motivated adequately. Bicuspidization is a procedure, which in a properly selected case can facilitate retention of the tooth in a functional state
Amlodipine induced gingival enlargement
Drug-induced gingival overgrowth or enlargement is an abnormal growth of the gingiva due to an adverse drug reaction in patients treated with anticonvulsants, immunosuppressants, and calcium channel blockers (CCBs). CCBs are considered as one of the etiologic factors among patients seeking dental care for drug-induced gingival enlargement or overgrowth. This enlargement can be localized or generalized and can range from mild to extremely severe, affecting patient's appearance, and function. CCBs are one of the most commonly used drugs for the management of cardiovascular disorders and are known for causing gingival over growth. Amlodipine is a new CCB and has been used with increasing frequency in the management of hypertension and angina. Although amlodipine is considered as a safe drug, very rarely it may induce gingival overgrowth. A rare case of amlodipine-induced gingival overgrowth has been reported herein a 45-year-old female patient. The treatment aspect included scaling and root planing, substitution of the drug, the surgical excision, and the maintenance and supportive therapy resulting in an excellent clinical outcome
Not Available
Not AvailableThe family Symphysanodontidae comprises of
small to medium sized bony fishes commonly known
as banquelovelies, slopefishes and insular shelf
beauties. They are caught in trawls operating in
depths from 50 to 500 m, mainly on the continental
shelf and slopes.Not Availabl